Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ebos GroupEBOSY 85 Cash-to-Debt is 0.14 as of Dec. 2025, which is 44% below its 10-year median of 0.25. GuruFocus rates EBOSY with a GF Score™ of 85/100 and a GF Value™ of $47.52. The stock has 4 warning signs investors should review. Among 118 Medical Distribution companies, Ebos Group ranks worse than 79.66% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ebos Group's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.14.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Ebos Groupcouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Ebos Group's Cash-to-Debt or its related term are showing as below:
EBOSY'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11 Med: 0.25 Max: 0.94
Current: 0.14
During the past 13 years, Ebos Group's highest Cash to Debt Ratio was 0.94. The lowest was 0.11. And the median was 0.25.
EBOSY's Cash-to-Debt is ranked worse than 79.66% of 118
companies
in the Medical Distribution industry
Industry Median: 0.65
vs EBOSY: 0.14
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Ebos Group Cash-to-Debt Related Terms
Ebos Group Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Ebos Group's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Distribution subindustry, Ebos Group's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group Cash-to-Debt vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Ebos Group's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ebos Group (EBOSY) has a Cash-to-Debt of 0.14 as of Dec. 2025. This is 44% below median its historical median of 0.25. Over the past decade, Ebos Group's Cash-to-Debt has ranged from 0.11 to 0.94. According to the industry distribution chart, Ebos Group ranks #94 out of 118 companies in the Medical Distribution industry, placing it in the top 79.7%.
Is Ebos Group's Cash-to-Debt too high?
Ebos Group's current Cash-to-Debt of 0.14 is 44% below median its 10-year median of 0.25. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 0.94. The Medical Distribution industry median Cash-to-Debt is 0.65. Ebos Group's value of 0.14 is 78.5% below this industry median. Based on the distribution chart, Ebos Group ranks #94 out of 118 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Ebos Group has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Cash-to-Debt compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #94 out of 118 companies for Cash-to-Debt. This places Ebos Group in the lower half of its industry. The industry median Cash-to-Debt is 0.65. Ebos Group's value of 0.14 is 78.5% below this benchmark. Historically, Ebos Group's own Cash-to-Debt has ranged from 0.11 to 0.94 over the past decade. While the company's 10-year median is 0.25 vs. the industry median of 0.65, Ebos Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Distribution company?
The median Cash-to-Debt among Medical Distribution companies is 0.65, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current Cash-to-Debt of 0.14 is 78.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median Cash-to-Debt is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current Cash-to-Debt is 0.14, which is 44% below median its own 10-year median of 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Ebos Group (EBOSY) has a current Cash-to-Debt of 0.14. The stock's GF Value™ is $47.52, compared to a current price of $26.00 — trading 45.3% below its estimated fair value. The current Cash-to-Debt is 0.14, which is 44% below median its 10-year median of 0.25 and 78.5% below the Medical Distribution industry median of 0.65. Ebos Group's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Ebos Group (EBOSY), the current Cash-to-Debt is 0.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (EBOSY) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of $26.00 is trading 45.3% below its estimated GF Value™ of $47.52.
Key valuation signals for EBOSY:
Cash-to-Debt: 0.14 (44% below median its 10-year median of 0.25)
GF Value™: $47.52 vs. price of $26.00 (45.3% below fair value)
Industry Position: 78.5% below the Medical Distribution median (#94 of 118)
No single metric tells the full story. See the EBOSY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
85GF Score
Get the complete analysis for EBOSY
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EBOSY has been successfully added to your 
